BeyondSpring Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeyondSpring in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BeyondSpring stock.
View analyst ratings for BeyondSpring or view top-rated stocks.

Wall Street analysts have given BeyondSpring a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BeyondSpring wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

BeyondSpring saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 2,230,000 shares, an increase of 23.9% from the August 15th total of 1,800,000 shares. Based on an average daily volume of 3,090,000 shares, the short-interest ratio is currently 0.7 days. Currently, 10.9% of the company's stock are sold short.
View BeyondSpring's Short Interest.

BeyondSpring is scheduled to release its next quarterly earnings announcement on Tuesday, November 16th 2021.
View our earnings forecast for BeyondSpring.

BeyondSpring Inc. (NASDAQ:BYSI) announced its quarterly earnings results on Thursday, September, 9th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.49). During the same quarter in the previous year, the company posted ($0.46) EPS.
View BeyondSpring's earnings history.

BeyondSpring's stock was trading at $11.35 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BYSI stock has increased by 33.5% and is now trading at $15.15.
View which stocks have been most impacted by COVID-19.

5 equities research analysts have issued twelve-month price targets for BeyondSpring's stock. Their forecasts range from $25.00 to $95.00. On average, they expect BeyondSpring's stock price to reach $58.75 in the next twelve months. This suggests a possible upside of 287.8% from the stock's current price.
View analysts' price targets for BeyondSpring or view top-rated stocks among Wall Street analysts.

Some companies that are related to BeyondSpring include Taro Pharmaceutical Industries (TARO), Corcept Therapeutics (CORT), Morphic (MORF), Verve Therapeutics (VERV), Indivior (INVVY), Dynavax Technologies (DVAX), Harmony Biosciences (HRMY), Nuvation Bio (NUVB), Cassava Sciences (SAVA), Amarin (AMRN), Rocket Pharmaceuticals (RCKT), Organogenesis (ORGO), Ironwood Pharmaceuticals (IRWD), Revance Therapeutics (RVNC) and Myovant Sciences (MYOV).
View all of BYSI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BeyondSpring investors own include Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Enterprise Products Partners (EPD), Johnson & Johnson (JNJ), Pfizer (PFE), Atara Biotherapeutics (ATRA), CorMedix (CRMD) and Dynavax Technologies (DVAX).

(BYSI) raised $4 million in an initial public offering (IPO) on Thursday, March 9th 2017. The company issued 200,000 shares at a price of $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) acted as the underwriter for the IPO.

BeyondSpring trades on the NASDAQ under the ticker symbol "BYSI."

BeyondSpring's stock is owned by a number of retail and institutional investors. Top institutional investors include Alliancebernstein L.P. (7.69%), BlackRock Inc. (3.63%), Blair William & Co. IL (1.10%), State Street Corp (0.79%), Northern Trust Corp (0.56%) and Geode Capital Management LLC (0.51%).

BYSI stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Marshall Wace LLP, Bank of America Corp DE, Nuveen Asset Management LLC, JPMorgan Chase & Co., Morgan Stanley, Morgan Stanley, and Diametric Capital LP.

BYSI stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., BlackRock Inc., Blair William & Co. IL, Apis Capital Advisors LLC, Citadel Advisors LLC, Susquehanna International Group LLP, Parametric Portfolio Associates LLC, and Geode Capital Management LLC.

Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BYSI stock can currently be purchased for approximately $15.15.

BeyondSpring has a market capitalization of $592.46 million and generates $180,000.00 in revenue each year. The company earns $-60,970,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis.

BeyondSpring employs 91 workers across the globe.

The official website for BeyondSpring is www.beyondspringpharma.com.

BeyondSpring is headquartered at 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005.

BeyondSpring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at (646) 305-6387 or via email at [email protected].